Somatostatin Analogs - Octreotide Immediate‑Release Products Prior Authorization Policy
Prior authorization requirements and medical necessity criteria for coverage of octreotide immediate‑release products (Bynfezia Pen, Sandostatin and generics) for prescription benefit plans administered by Cigna companies, describing approved indications, durations, and specialty prescriber requirements.
Enterocutaneous fistulas added as an 'Other Uses with Supportive Evidence' approval with criteria and 3‑month approval.
Pancreatic fistulas added as an 'Other Uses with Supportive Evidence' approval with 2‑month approval for specific settings.
Diarrhea associated with chemotherapy added as an 'Other Uses with Supportive Evidence' approval (3‑month) with Grade 3–4 requirement and prior antimotility trial.
Small bowel bleeds/angiodysplasia related bleeding added as an approval for 6 months with chronicity requirement (≥3 months) and gastroenterology prescriber.
A clarifying note was added providing examples of Grade 3 or Grade 4 diarrhea.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.